In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.
By comparing viruses in parts of China with or without endemic EBV-associated nasal cancers, researchers narrowed in on two viral variants associated with increased cancer risk.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The newly launched RT-PCR-based molecular diagnostic kits are designed for use in monitoring post-transplantation and immunosuppressed patients.
The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.
Cincinnati Children's Hospital Medical Center researchers found that disease risk loci overlap with transcription factor binding sites.
Researchers use the CRISPR/Cas9 gene editing approach to limit herpesviruses replication.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.
BioMérieux plans to migrate Argene's test products onto a molecular diagnostic platform it is co-developing with Biocartis.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.